Total Payments
$695,369
2024 Payments
$191,597
Companies
52
Transactions
861
Medicare Patients
7,850
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$376,463 (54.1%)
Consulting$228,688 (32.9%)
Travel$66,036 (9.5%)
Food & Beverage$22,323 (3.2%)
Research$1,585 (0.2%)
Education$275.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $329,468 | 135 | 47.4% |
| Consulting Fee | $228,688 | 135 | 32.9% |
| Travel and Lodging | $66,036 | 178 | 9.5% |
| Honoraria | $42,495 | 18 | 6.1% |
| Food and Beverage | $22,323 | 383 | 3.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,500 | 2 | 0.6% |
| Unspecified | $1,585 | 4 | 0.2% |
| Education | $275.17 | 6 | 0.0% |
Payments by Type
General
$693,784
857 transactions
Research
$1,585
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $120,075 | 89 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $100,512 | 99 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $88,404 | 93 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $52,125 | 82 | $0 (2024) |
| G1 Therapeutics, Inc. | $47,111 | 42 | $0 (2023) |
| EMD Serono, Inc. | $44,044 | 41 | $0 (2024) |
| Amgen Inc. | $41,930 | 48 | $0 (2024) |
| Mirati Therapeutics, Inc. | $34,267 | 34 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $32,130 | 30 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $19,409 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $191,597 | 262 | JAZZ PHARMACEUTICALS INC. ($58,131) |
| 2023 | $301,425 | 310 | Regeneron Healthcare Solutions, Inc. ($70,431) |
| 2022 | $139,354 | 187 | E.R. Squibb & Sons, L.L.C. ($44,599) |
| 2021 | $49,149 | 49 | E.R. Squibb & Sons, L.L.C. ($28,622) |
| 2020 | $12,524 | 27 | AstraZeneca Pharmaceuticals LP ($5,575) |
| 2019 | $1,230 | 21 | Ipsen Biopharmaceuticals, Inc ($863.25) |
| 2018 | $89.38 | 5 | AstraZeneca Pharmaceuticals LP ($77.71) |
All Payment Transactions
861 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $123.80 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/20/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,664.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $460.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/13/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Alecensa (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,880.00 | General |
| Category: BioOncology | ||||||
| 12/06/2024 | Lilly USA, LLC | RETEVMO (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Lilly USA, LLC | RETEVMO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: HEMATOLOGY | ||||||
| 12/04/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $394.05 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% • Category: ONCOLOGY | ||||||
| 12/03/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $862.50 | General |
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,675.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $457.50 | General |
| 11/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $139.95 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/23/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $36.96 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/23/2024 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $25.11 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,156.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $921.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $578.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $307.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $35.81 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/21/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $320.85 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | Regeneron Pharmaceuticals, Inc. | $1,585 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 49 | 2,190 | 27,459 | $2.6M | $607,477 |
| 2022 | 56 | 2,356 | 33,590 | $2.3M | $478,230 |
| 2021 | 49 | 1,834 | 12,659 | $1.2M | $261,935 |
| 2020 | 40 | 1,470 | 7,433 | $613,683 | $92,776 |
Total Patients
7,850
Total Services
81,141
Medicare Billing
$1.4M
Procedure Codes
194
All Medicare Procedures & Services
194 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 5,600 | $1.1M | $245,807 | 23.3% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 4,500 | $736,875 | $173,156 | 23.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 25 | 2,760 | $194,221 | $52,013 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 185 | $75,771 | $16,559 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 104 | 212 | $61,064 | $12,374 | 20.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 20 | 4,500 | $49,185 | $10,503 | 21.4% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 30 | 139 | $9,730 | $10,447 | 107.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 80 | 111 | $50,482 | $10,260 | 20.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 135 | 248 | $44,282 | $9,181 | 20.7% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 17 | 25 | $40,868 | $8,444 | 20.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 180 | 808 | $21,935 | $6,120 | 27.9% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 165 | 700 | $20,678 | $5,777 | 27.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 49 | $27,597 | $5,749 | 20.8% |
| 80076 | Liver function blood test panel | Office | 2023 | 164 | 685 | $19,544 | $5,462 | 27.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 128 | 442 | $12,554 | $3,692 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 28 | $16,105 | $3,590 | 22.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 73 | 157 | $14,265 | $3,282 | 23.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 35 | 54 | $13,695 | $2,812 | 20.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 40 | 158 | $9,290 | $2,601 | 28.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $11,263 | $2,501 | 22.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 45 | $8,929 | $2,062 | 23.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 38 | $8,386 | $1,727 | 20.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $5,862 | $1,201 | 20.5% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 27 | $5,293 | $1,200 | 22.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 19 | $4,870 | $1,082 | 22.2% |
About Dr. Jason Porter, M.D
Dr. Jason Porter, M.D is a Hematology & Oncology healthcare provider based in Germantown, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2013. The National Provider Identifier (NPI) number assigned to this provider is 1780927244.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Porter, M.D has received a total of $695,369 in payments from pharmaceutical and medical device companies, with $191,597 received in 2024. These payments were reported across 861 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($329,468).
As a Medicare-enrolled provider, Porter has provided services to 7,850 Medicare beneficiaries, totaling 81,141 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 194 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Germantown, TN
- Active Since 04/03/2013
- Last Updated 07/15/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1780927244
Products in Payments
- LIBTAYO (Biological) $151,571
- OPDIVO (Biological) $94,819
- ZEPZELCA (Drug) $88,204
- COSELA (Drug) $47,127
- KRAZATI (Drug) $34,267
- EXKIVITY (Drug) $25,329
- TEPMETKO (Drug) $19,313
- LUMAKRAS (Drug) $10,133
- TAGRISSO (Drug) $9,650
- Trodelvy (Drug) $8,689
- Optune Lua (NovoTTF-200T) (Device) $8,394
- KEYTRUDA (Biological) $8,071
- ALUNBRIG (Drug) $6,766
- IMFINZI (Biological) $6,579
- TABRECTA (Drug) $6,012
- RYBREVANT (Drug) $5,641
- TECENTRIQ (Biological) $5,338
- MEKINIST (Drug) $4,808
- RETEVMO (Drug) $3,361
- Tepmetko (Drug) $3,315
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Germantown
Axel Grothey, M.d, M.D
Hematology & Oncology — Payments: $395,090
Hematology & Oncology $395,090
Bradley Somer, Md, MD
Hematology & Oncology — Payments: $117,191
Hematology & Oncology $117,191
Dr. Timothy Goggins, M.d, M.D
Hematology & Oncology — Payments: $91,094
Hematology & Oncology $91,094
Mr. Gang Tian, M.d, M.D
Hematology & Oncology — Payments: $67,957
Hematology & Oncology $67,957
Sylvia Richey, Md, MD
Hematology & Oncology — Payments: $26,784
Hematology & Oncology $26,784
Dr. Albert Weeks, M.d, M.D
Hematology & Oncology — Payments: $21,707
Hematology & Oncology $21,707